May 10 (Reuters) - Novavax Inc said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study. (https://refini.tv/3bg25TM) (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | +98.66% | +80.12% | +85.00% |
May. 11 | Wall Street closes up ahead of inflation data | RE |
May. 10 | News Highlights : Top Company News of the Day - Friday at 5 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+85.00% | 1.25B | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.56% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : combined influenza/COVID-19 vaccine shows promise in preclinical study